Patients with rheumatoid arthritis (RA) in health maintenance organizations (HMOs) receive about the same amount of care as those not in HMOs, but they are much less likely to receive new medications for RA, new research suggests.
The new drugs included in the analysis were etanercept or infliximab (i.e., anti-TNF-alpha) and COX-2 inhibitors.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!